We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Gyros® AB announces the signing of a distribution agreement with DI Biotech, a supplier to the Korean life-science market.

Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries.

Gyrolab has become established as the preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organizations, in their drug development process and clinical trials, in both Europe and the USA.

As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Wallden, CEO and President of Gyros. “It’s an organization with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. Korea is committed to the growing biotherapeutics development segment and we are looking forward to supplying enabling technology to various ongoing initiatives in the country,” he concludes.